Clinical implication of plasma-derived circulating tumor DNA (ctDNA) changes in patients with advanced diffuse large B-cell lymphoma treated with immunochemotherapy

Chonnam National University Hospital Hwasun Hospital0 个研究点目标入组 53 人开始时间: 待定最近更新: 2023年8月1日

试验速览

暂无简介。

•1. Patients with histologically confirmed diffuse large B-cell lymphoma
•2. Over 18 years of age
•3. Ann Arbor Stage III or IV
•4. Bulky mass (= 8 cm) during Ann Arber Stage I or II
•5. Patients who have not previously been treated for diffuse large B-cell lymphoma
•6. Patients whose activity level is 0-2 based on ECOG
•7. One or more two-dimensionally measured lesions (if there is only one lesion, histological confirmation is required)
•8. Patients whose proper bone marrow, liver, and renal functions have been confirmed through tests conducted within one month of patient registration
•9. Patients whose life expectancy is expected to be more than 6 months
•10. For non-medical menopausal patients (pre-menopausal women or women with amenorrhea for less than 1 year), patients who have a negative serum or urine pregnancy test
•11. Patients who voluntarily decided to participate in this study and gave written consent

•1. HIV-positive patients
•2. Women of childbearing potential who are pregnant, lactating, or not using adequate contraception
•3. Systemic diseases for which anticancer drug administration is inappropriate
•4. Patients receiving other test drugs during clinical trials, or receiving chemotherapy, hormone therapy or immunotherapy in combination
•5. Patients with a history of other types of malignant tumors

发起方

Chonnam National University Hospital Hwasun Hospital